BBR Partners LLC Trims Stake in GE HealthCare Technologies Inc. (NASDAQ:GEHC)

BBR Partners LLC reduced its position in GE HealthCare Technologies Inc. (NASDAQ:GEHC) by 8.4% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 5,508 shares of the company’s stock after selling 506 shares during the quarter. BBR Partners LLC’s holdings in GE HealthCare Technologies were worth $431,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Bay Colony Advisory Group Inc d b a Bay Colony Advisors raised its position in GE HealthCare Technologies by 2.1% in the 4th quarter. Bay Colony Advisory Group Inc d b a Bay Colony Advisors now owns 7,297 shares of the company’s stock worth $571,000 after purchasing an additional 153 shares during the period. Callan Family Office LLC bought a new position in GE HealthCare Technologies in the 4th quarter worth about $1,344,000. E Fund Management Co. Ltd. grew its stake in GE HealthCare Technologies by 50.8% in the 4th quarter. E Fund Management Co. Ltd. now owns 10,526 shares of the company’s stock worth $823,000 after acquiring an additional 3,545 shares in the last quarter. PFG Private Wealth Management LLC bought a new position in GE HealthCare Technologies in the 4th quarter worth about $198,000. Finally, Raymond James Financial Inc. bought a new position in GE HealthCare Technologies in the 4th quarter worth about $73,472,000. 82.06% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

GEHC has been the topic of a number of research analyst reports. Wells Fargo & Company upped their target price on shares of GE HealthCare Technologies from $96.00 to $103.00 and gave the stock an “overweight” rating in a research note on Friday, February 14th. Jefferies Financial Group upgraded shares of GE HealthCare Technologies from a “hold” rating to a “buy” rating and upped their target price for the stock from $95.00 to $103.00 in a research note on Wednesday, January 8th. Finally, Citigroup upped their target price on shares of GE HealthCare Technologies from $103.00 to $110.00 and gave the stock a “buy” rating in a research note on Thursday, February 13th. One analyst has rated the stock with a sell rating, three have issued a hold rating, eight have given a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $97.67.

GE HealthCare Technologies Price Performance

Shares of GEHC opened at $85.41 on Friday. The company has a market cap of $39.06 billion, a price-to-earnings ratio of 19.73, a price-to-earnings-growth ratio of 3.19 and a beta of 1.15. GE HealthCare Technologies Inc. has a twelve month low of $74.51 and a twelve month high of $94.80. The company has a quick ratio of 0.83, a current ratio of 1.04 and a debt-to-equity ratio of 0.88. The company has a 50 day moving average of $86.63 and a two-hundred day moving average of $86.13.

GE HealthCare Technologies (NASDAQ:GEHC) last announced its earnings results on Thursday, February 13th. The company reported $1.45 earnings per share for the quarter, beating the consensus estimate of $1.26 by $0.19. The company had revenue of $5.32 billion during the quarter, compared to the consensus estimate of $5.33 billion. GE HealthCare Technologies had a net margin of 10.13% and a return on equity of 25.74%. As a group, analysts predict that GE HealthCare Technologies Inc. will post 4.68 earnings per share for the current fiscal year.

About GE HealthCare Technologies

GE HealthCare Technologies Inc engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, and internationally. The company operates through four segments: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics.